Patents by Inventor Anandi Sawant

Anandi Sawant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS
    Publication number: 20250289890
    Abstract: Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.
    Type: Application
    Filed: June 3, 2025
    Publication date: September 18, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai
  • Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
    Patent number: 12358986
    Abstract: Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: July 15, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai
  • ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS
    Publication number: 20220411507
    Abstract: Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 29, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai